

# A Simple Two-Step Method for the Isolation of Human CD4<sup>+</sup>CD25<sup>bright</sup>/FOXP3<sup>+</sup> Regulatory T Cells Directly from Whole Blood


Benoit G. Guilbault<sup>1</sup>, Maureen A. Fairhurst<sup>1</sup>, Natasha K. Crellin<sup>2</sup>, Megan K. Levings<sup>2</sup>, Allen C. Eaves<sup>3</sup> and Terry E. Thomas<sup>1</sup>  
StemCell Technologies Inc<sup>1</sup>, The Dept. of Surgery, UBC & Immunity and Infection Research Centre, Vancouver Coastal Health Research Institute<sup>2</sup>, and Terry Fox Laboratory<sup>3</sup>, Vancouver, Canada.

## Introduction

Human CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells (T<sub>R</sub>) have the ability to suppress T cell responses and have recently been shown to play a critical role in peripheral tolerance and regulation of immune responses. CD4<sup>+</sup>CD25<sup>+</sup> T<sub>R</sub> are anergic, phenotypically CD25<sup>bright</sup> and express high levels of the transcription factor FOXP3. Peripheral blood T<sub>R</sub> are rare and must be highly enriched for their suppressor function to be detected in vitro. This, combined with the lack of a unique marker that distinguishes them from activated T cells, makes it difficult to study T<sub>R</sub> function and evaluate their therapeutic potential. Current methods for isolating T<sub>R</sub> are cumbersome and time-consuming, and generally require three steps: Ficoll™ density centrifugation to isolate mononuclear cells; subsequent immunomagnetic T cell enrichment; and finally FACS sorting. The objective of this study was to develop a more simple technique to isolate highly purified T<sub>R</sub> from whole blood without using FACS sorting.

## Methods

**Figure 1. Isolation of CD4<sup>+</sup>CD25<sup>+</sup> and CD4<sup>+</sup>CD25<sup>neg</sup> T cell populations from whole blood using RosetteSep® and EasySep® technologies.**




Three steps were reduced to two by replacing the Ficoll™ separation and immunomagnetic T cell enrichment with a single antibody-mediated buoyant density centrifugation (RosetteSep®) to enrich CD4 T cells directly from whole blood. A cocktail of bi-specific antibodies were used to selectively bind unwanted cells to red cells causing them to pellet when centrifuged over Ficoll™. Purified CD4 T cells were recovered at the plasma-Ficoll™ interface and then separated using EasySep® column-free magnetic separation to select CD25 expressing cells. The EasySep® separation conditions were optimized for maximal CD4<sup>+</sup>CD25<sup>bright</sup> T cell purity and recovery.

Ficoll™ and Ficoll-Paque™ are trademarks of GE Healthcare Ltd.


## Results

**Figure 2. Phenotypic characterization of cell populations isolated from whole blood.**




Both CD4<sup>+</sup>CD25<sup>+</sup> and CD4<sup>+</sup>CD25<sup>neg</sup> T cell populations were isolated by combining RosetteSep® CD4 T cell enrichment and EasySep® CD25 selection. Following RosetteSep® enrichment of CD4 T cells, CD4<sup>+</sup>CD25<sup>+</sup> populations were isolated with the EasySep® CD25 selection kit using the manufacturer's suggested protocol. The CD25 positively selected fraction was 94 ± 3% (n=6) CD4<sup>+</sup>CD25<sup>+</sup> and 83 ± 7% (n=6) CD4<sup>+</sup>CD25<sup>bright</sup>. The CD4<sup>+</sup>CD25<sup>neg</sup> T cell populations recovered in the unselected fraction were further depleted from CD25 expressing cells with the EasySep® CD25 selection kit using a depletion protocol provided by the manufacturer.

**Figure 3. Phenotypic characterization of isolated CD4<sup>+</sup>CD25<sup>+</sup> T cells.**




CD4<sup>+</sup>CD25<sup>+</sup> T cell populations isolated as in Figure 2 were characterized by staining with fluorochrome-conjugated anti-CD4 and CD25 antibodies in combination with either anti-CD62L or anti-HLA-DR antibodies. Intracellular CTLA-4 expression was determined by staining cells with an anti-CTLA-4 antibody following fixing with 2% formaldehyde, and permeabilization with saponin. Cells were analysed by flow cytometry.

**Figure 4. FOXP3 measurements in isolated CD4<sup>+</sup>CD25<sup>+</sup> T cells.**



FOXP3 mRNA levels in isolated CD4<sup>+</sup>CD25<sup>+</sup> T cell fractions were compared to control CD4<sup>+</sup>CD25<sup>neg</sup> T cell fractions using quantitative PCR. For simplicity, CD4<sup>+</sup>CD25<sup>neg</sup> FOXP3 values were assigned the value 1, and CD4<sup>+</sup>CD25<sup>+</sup> FOXP3 levels are expressed relative to 1 with the Bar indicating the mean of 4 donors and the error bar indicating standard deviation.

**Figure 5. Isolated CD4<sup>+</sup>CD25<sup>+</sup> T cells are anergic and suppress proliferation of CD4<sup>+</sup>CD25<sup>neg</sup> T cells.**



Purified CD4<sup>+</sup>CD25<sup>+</sup> T cell fractions were assessed for anergy by measuring their proliferation response to anti-CD3/CD28 coated beads (in grey). The suppression activity of purified CD4<sup>+</sup>CD25<sup>+</sup> T cells was assessed by measuring their ability to reduce the proliferative response of CD4<sup>+</sup>CD25<sup>neg</sup> T cells to CD3/CD28 beads (in black). T cell proliferation was quantified by measuring dilution of the fluorescent dye CFSE with flow cytometry. Results are expressed as proliferation detected relative to control CD4<sup>+</sup>CD25<sup>neg</sup> cell populations stimulated with CD3/28 beads for 7 days in RPMI containing 5% human AB serum. The bars are the means of 5 experiments with error bars indicating standard deviations.

## Conclusions

- Combining RosetteSep® CD4 T cell enrichment with EasySep® CD25 selection yields highly pure CD4<sup>+</sup>CD25<sup>bright</sup> / FOXP3<sup>+</sup> T<sub>R</sub> in less time and with fewer steps than current isolation methods.
- Isolated cells display characteristics of peripheral blood CD4<sup>+</sup>CD25<sup>+</sup> T<sub>R</sub>:
  - Expression of surface and intracellular markers such as CD62L, HLA-DR, and CTLA-4
  - Expression of FOXP3 at high levels
  - Ability to suppress T cell proliferation responses

**StemCell Technologies Inc**  
The Cell Experts  
www.stemcell.com

**Head Office**  
StemCell Technologies Inc  
570 West 7th Avenue, Suite 400  
Vancouver BC CANADA V5Z 1B3  
Tel: (604) 877-0713  
Fax: (604) 877-0704  
Toll Free Tel: 1-800-667-0322  
Toll Free Fax: 1-800-567-2899  
E-mail: info@stemcell.com  
Website: www.stemcell.com

**UK Office**  
Toll-free within United Kingdom  
Tel: 0800 731 27 14  
Fax: 0800 731 27 13  
E-mail: info@stemcell.com

**European Office**  
StemCell Technologies France  
miniparc Polytec  
batiment Tramontane  
60 rue des Berges  
3800 Grenoble FRANCE  
Tel: +33 (0)4 76 04 75 30  
Fax: +33 (0)4 76 18 99 63  
E-mail: info@stemcellfrance.com